CNSY Cerenome, Inc.
Company Analysis
Latest News
🔴 Cerenome is trading 5.1% down today amid broader market risk-off pressure
Cerenome is trading 5.1% down at $2.67 as broader risk-off conditions pressure equities. - No new company-specific announcement was identified for September...
🔴 Cerenome is trading 6.23% down today
Cerenome is trading at $2.86, down -6.23%, with no company-specific announcement identified for August 31, 2026. - The latest investor-relations release is...
🟢 Cerenome is trading 5.6% up today as broader markets strengthen
Cerenome is trading at $3.19, up +5.63%, most likely reflecting broad market strength rather than a confirmed company-specific catalyst. - S&P 500 and Nasdaq...
🟢 Cerenome is trading 5% up today as softer confidence data supports rate-cut hopes
Cerenome is trading 5% up at $3.11, with the move appearing consistent with broader risk-on sentiment. - No new company-specific announcement dated August 25,...
🔴 Cerenome is trading 5.3% down today; immediate catalyst unclear
Cerenome is trading 5.3% down at $3.02, with the immediate catalyst unclear. - No company-specific announcement has been explicitly linked to the August 20,...
🔴 Cerenome is trading 10% down today after Q2 results missed EPS and revenue estimates
Cerenome is trading at $3.31 (-10.05%) after investors reacted to its August 14, 2026 second-quarter results. • Q2 loss reached $9.0 million, or $1.31 per...
🔴 Cerenome is trading 9.78% down in pre-market after reporting a $9.0 million second-quarter loss
Cerenome is trading at $3.32, down 9.78% in pre-market on August 17, 2026, after reporting a $9.0 million second-quarter loss and $1.31 loss per share. -...
🔴 Cerenome is trading 10.33% down in after-hours trading after second-quarter loss per share missed estimates
Cerenome is trading at $3.30 (-10.33%) in after-hours trading after its second-quarter loss per share missed estimates. - Cerenome reported a $9.0 million...
Cerenome's second quarter 2026 loss of $9M highlights strategic rebrand and clinical trial expansion
Cerenome reported a significantly widened operating loss for the second quarter of 2026 as the company rebranded from Plus Therapeutics and accelerated its...
Cerenome's Fresh Rebrand Meets a Harsh Reality Check — Can a 28-Person Company Survive a $9 Million Quarterly Burn?
Shares of Cerenome (CNSY) cratered 9.4% to $3.35 after the freshly rebranded brain-cancer diagnostics and therapeutics company posted second-quarter results...
🔴 Cerenome is trading 8.91% down in after-hours trading after reporting a $9.0 million Q2 net loss
Cerenome is trading 8.91% down at $3.35 in after-hours trading after releasing second-quarter results on August 14, 2026. - Q2 net loss was $9.0 million, or...
🟢 Cerenome is trading 6% up after agreement adds 27.3 million covered lives
Cerenome is trading at $3.92, up 5.95%, on August 13, 2026, after announcing an in-network agreement with Health Care Service Corporation. - The agreement...
🟢 Cerenome is trading 6% up in pre-market after in-network agreement expands CNSide access
Cerenome is trading 6.10% up in pre-market at $3.93 after announcing an in-network agreement with Health Care Service Corporation on August 13, 2026. - The...
Cerenome, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 13, 2026
Consensus estimates for Cerenome, Inc. project a Q2 2026 loss of $0.96 per share on revenue of $1.11 million, with the micro-cap stock trading at $3.84 against...